Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.   

RSS icon
A heart attack is caused when one of the coronary arteries becomes blocked with a clot.

Texas researchers receive $1.14M to develop first CVD drug of its kind

If successful, the group's first-in-class medication would be able to target inflammation in CVD patients before it even occurs. 

August 25, 2023
pills-384846_960_720.jpg

Missed opportunities: Many high-risk patients still not taking aspirin to prevent CVD

Aspirin is known to be an effective, affordable way to prevent cardiovascular disease.

August 22, 2023
A complete list of the European Society of Cardiology (ESC) 2023 Congress late-breaking Hot Line sessions. #ESCCongress

ESC Congress 2023 to feature 30 late-breaking clinical trials

The European Society of Cardiology's annual meeting is scheduled for Aug. 25-28, 2023, in Amsterdam.

August 18, 2023
doctor with overweight patient who may be treated with TAVR or surgery

Weight loss drug semaglutide could boost heart health of up to 93M patients in US alone

Researchers have recently determined that the medication, originally developed to treat diabetes, can contribute to weight loss and reduce a patient's MACE risk by up to 20%. 

August 15, 2023
The U.S. Food and Drug Administration (FDA) has issued a new draft guidance designed to help applicants add clinically relevant information about QTc interval prolongation to the labeling of non-antiarrhythmic drugs

FDA highlights importance of including heart rhythm risks on drug labels

The agency has shared a new draft guidance focused on the inclusion of information related to QTc interval prolongation. 

August 10, 2023
Video of Hari Naidu, MD, director of the Hypertrophic Cardiomyopathy Center of Excellence at Westchester Medical Center, explaining the role of alcohol septal ablation and surgical myectomy in the era of mavacamten. #HCM #ASE

Surgery, interventional therapies still the best choice for many HCM patients

"You have to look at each patient and understand their goals," one HCM expert said in a new interview. 

August 9, 2023
Weekly doses of semaglutide, a GLP-1 receptor originally developed to treat diabetes, could help approximately 93 million U.S. adults lose weight and reduce their risk of adverse cardiovascular events, according to new research published in Cardiovascular Drugs and Therapy. Novo Nordisk sells and markets subcutaneous treatments of semaglutide 2.4 mg under the brand name Wegovy.

Weight loss drug semaglutide reduces risk of adverse cardiovascular events by 20% among overweight, obese patients

Weekly subcutaneous treatments of semaglutide, originally developed to treat diabetes, are sold and marketed under the brand name Wegovy.

August 8, 2023
Interventional cardiologists performing PCI

Colchicine before PCI: New research tracks the long-term impact on heart health

Researchers shared long-term follow-up data from the Colchicine-PCI trial, which compared colchicine administration before PCI with a placebo.

August 7, 2023
Displaying 57 - 64 of 231

Around the web

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Design by Adaptive Theme
Trimed Popup
Trimed Popup